Status:
RECRUITING
The Impact of Time Restricted Eating on Type 2 Diabetes
Lead Sponsor:
Rockefeller University
Collaborating Sponsors:
NYU Langone Health
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Time-restricted feeding limits caloric intake to active daytime hours with fasting for 14 to 16 hours. It has shown great promise as a novel intervention for stabilizing blood glucose, reducing weight...
Detailed Description
Early Time Restricted Eating (eTRE) is a meal timing strategy that restricts the daily eating window to the first 6-8 waking hours of the day, while extending the fasting window between the final meal...
Eligibility Criteria
Inclusion
- Age 18-75 able to give consent
- BMI \>25 kg/m2
- Hemoglobin A1C ≥ 6.5%
- Willing to eat only the food provided
- Willing to follow the feeding schedule, including fasting for 16 hours/day for six days.
- Usual sleep time is between 10 PM and 8 AM
- Fluent in the English language
Exclusion
- Current use of anti-obesity medications (Ozempic, Mounjaro, Trulicity, Wegovy, Zepbound, Qsymia, Contrave, Saxenda, Victoza, Orlistat)
- Report history of Cirrhosis
- HIV positive
- Self-reported autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, psoriasis, etc.)
- Current use of steroids (inhalers are permissible)
- Currently pregnant
- Smoked tobacco within the last 3 months
- Allergy to adhesive tape
- Skips breakfast
- Followed TRF or intermittent fasting in the last 2 weeks
- Shift or night worker
- Current use of insulin
- Current use of sulfonylureas
- Current use of glucagon-like peptide-1 (GLP-1) receptor agonists
- Hemoglobin A1c \>8%
- Unable to sync smartphone with Bluetooth for scale data
- Any medical, psychological, or social condition that, in the opinion of the investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.
Key Trial Info
Start Date :
May 29 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2028
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06887543
Start Date
May 29 2025
End Date
March 30 2028
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Rockefeller University Hospital
New York, New York, United States, 10065